Back to search
FDAFDA · Food and drugs·Recall number D-1488-2020

VILEVEV MB Urinary Antispetic (81.0 mg methenamine, 40.8 mg sodium phosphate monobasic and 10.8 mg methylene blue, 0.12 mg hyoscyamine sulfate and 32.4 mg phenyl salicylate), Rx Only, 90 Tablets per Bottle, Manufactured for: Vilvet Pharmaceuticals, Inc., Chester Springs, PA 19425, NDC 71186-000-24.

Published August 12, 2020 · Recall initiated: July 24, 2020

Summary

FDA records drug Class II recall D-1488-2020, published August 12, 2020 and initiated July 24, 2020. Recalling firm: Vilvet Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 1,716 bottles; Lot: LOT M823J18-1, M823J18-2, M823J18-3 EXP 09/20; LOT M823D19-1 EXP 04/21. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Vilvet Pharmaceuticals Inc.
Distributor
Nationwide within the US
Lot
LOT M823J18-1, M823J18-2, M823J18-3 EXP 09/20; LOT M823D19-1 EXP 04/21
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was VILEVEV MB Urinary Antispetic (81.0 mg methenamine, 40.8 mg sodium phosphate monobasic and 10.8 mg methylene blue, 0.12 mg hyoscyamine sulfate and 32.4 mg phenyl salicylate), Rx Only, 90 Tablets per Bottle, Manufactured for: Vilvet Pharmaceuticals, Inc., Chester Springs, PA 19425, NDC 71186-000-24. recalled?

Yes. FDA published recall D-1488-2020 on August 12, 2020. Reported hazard: cGMP deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter